Amgen Q1 Earnings Preview: Obesity treatment updates to be the focus this season [Seeking Alpha]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Seeking Alpha
Analysts estimate a profit of $3.91 per share (-1.8% Y/Y) on revenue of $7.45B (+22.1% Y/Y). The company is expected to post in-line results and investors will be looking out for comments around its obesity portfolio, a space where it is directly competing with the likes of Eli Lilly and Novo Nordisk. According to J.P Morgan, “The focus of the AMGN story remains squarely on obesity. And while AMGN currently has the best potential of any large cap name to emerge as a third player in this rapidly growing space (although well behind LLY/Novo), questions on the asset's role in the market remain.” Over the last 2 years, AMGN has beaten EPS estimates 75% of the time and has beaten revenue estimates 75% of the time. Over the last 3 months, EPS estimates have seen 2 upward revisions and 7 downward. Revenue estimates have seen 4 upward revisions and 2 downward. “We remain sceptical but will be watching closely as the MariTide event path is the primary driver of sentiment/ valuation
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Ozempic maker Novo Nordisk says it will study drug's effects on alcohol consumption but isn't focused on addiction [Yahoo! Finance]Yahoo! Finance
- Ozempic maker Novo Nordisk says it will study drug's effects on alcohol consumption but isn't focused on addiction [CNN]CNN
- Wegovy users may keep the weight off for 4 years, drug's maker says [CBS News]CBS News
- Ozempic maker Novo Nordisk says it will study drug's effects on alcohol consumption but isn't focused on addiction [CNN]CNN
- UK weight-loss drug price rivalry intensifies with Pharmacy2U mark-down [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 5/3/24 - Beat
NVO
Sec Filings
- 5/15/24 - Form 6-K
- 5/13/24 - Form 6-K
- 5/13/24 - Form 6-K
- NVO's page on the SEC website